{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974035",
  "id": "02974035",
  "pages": 12,
  "price_sensitive": true,
  "date": "20250729",
  "time": "1741",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m8ln6h4687z3.pdf",
  "summary": "### Quarterly Report (Appendix 4C) Summary:  \n\n#### **Financial & Operational Highlights**  \n- **Closing cash balance**: $5.121 million (down from $5.440 million previous quarter); includes $3.247 million from capital raise (part of $8.7M total).  \n- **Quarterly cash burn (operating activities)**: Net cash used: **$3.296M** (60% attributed to staff costs and R&D).  \n- **Sales growth**:  \n  - **Q4 FY25 dose sales**: Record 20% quarter-on-quarter increase.  \n  - **FY25 annual sales**: 42% dose growth, 66% revenue uplift vs. FY24.  \n- **Capital consolidation**: Completed 1-for-400 share consolidation.  \n\n#### **Clinical & Commercial Developments**  \n- **G-BA (Germany) tender**: Initiated for a CRO to conduct pivotal clinical study supporting reimbursement (tender closed 11 June 2025).  \n- **Clinical data (DDW 2025)**: OncoSil\u2122 showed superior outcomes vs. SBRT in LAPC:  \n  - **22 vs. 14 months median survival** (HR: 1.98; p=0.004).  \n  - **22% surgical resection rate** vs. 0% for SBRT (p<0.001).  \n- **Distribution expansion**: Signed exclusive agreement with **Pro-Gem** for Slovenia.  \n\n#### **Capital Raise Details**  \n- **Structure**: $8.7M total via Placement + SPP (oversubscribed to ~$4.5M).  \n- **Use of funds**: Clinical trials, working capital; extends runway to **H2 CY26** (projected cash flow breakeven).  \n\n#### **Post-Quarter Updates**  \n- **Clinical trials**: Completed recruitment for **PANCOSIL** (20 patients; data late 2025) and **TRIPP-FFX** (88 patients; data early 2026).  \n\n---  \n**Note**: Excluded non-material details (e.g., executive commentary, forward-looking statements, routine operational updates).",
  "usage": {
    "prompt_tokens": 7467,
    "completion_tokens": 450,
    "total_tokens": 7917,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T07:56:44.890821"
}